136197 20260217205545.0 doi 10.3389/fneur.2024.1417831 sideral 139155 ART-2024-139155 eng Navarro-Pérez, María Pilar (orcid)0000-0001-6370-218X Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study 2024 Access copy available to the general public Unrestricted Background: Real-world studies have shown the sustained therapeutic effect and favourable safety profile of OnabotulinumtoxinA (BoNTA) in the long term and up to 4 years of treatment in chronic migraine (CM). This study aims to assess the safety profile and efficacy of BoNTA in CM after 5 years of treatment in a real-life setting. Methods: We performed a retrospective chart review of patients with CM in relation to BoNTA treatment for more than 5 years in 19 Spanish headache clinics. We excluded patients who discontinued treatment due to lack of efficacy or poor tolerability. Results: 489 patients were included [mean age 49, 82.8% women]. The mean age of onset of migraine was 21.8 years; patients had CM with a mean of 6.4 years (20.8% fulfilled the aura criteria). At baseline, patients reported a mean of 24.7 monthly headache days (MHDs) and 15.7 monthly migraine days (MMDs). In relation to effectiveness, the responder rate was 59.1% and the mean reduction in MMDs was 9.4 days (15.7 to 6.3 days; p < 0.001). The MHDs were also reduced by 14.9 days (24.7 to 9.8 days; p < 0.001). Regarding the side effects, 17.5% experienced neck pain, 17.3% headache, 8.5% eyelid ptosis, 7.5% temporal muscle atrophy and 3.2% trapezius muscle atrophy. Furthermore, after longer-term exposure exceeding 5 years, there were no serious adverse events (AE) or treatment discontinuation because of safety or tolerability issues. Conclusion: Treatment with BoNTA led to sustained reductions in migraine frequency, even after long-term exposure exceeding 5 years, with no evidence of new safety concerns. info:eu-repo/semantics/openAccess by https://creativecommons.org/licenses/by/4.0/deed.es 2.8 2024 CLINICAL NEUROLOGY 121 / 286 = 0.423 2024 Q2 T2 NEUROSCIENCES 162 / 314 = 0.516 2024 Q3 T2 0.993 2024 Neurology (clinical) 2024 Q2 Neurology 2024 Q2 5.2 2024 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion González-Quintanilla, Vicente Muñoz-Vendrell, Albert Madrigal, Elisabet Alpuente, Alicia Latorre, Germán Molina, Francis Monzón, María José Medrano, Vicente García-Azorín, David González-Oria, Carmen Gago-Veiga, Ana Velasco, Fernando Beltrán, Isabel Morollón, Noemí Viguera, Javier Casas-Limón, Javier Rodríguez-Vico, Jaime Cuadrado, Elisa Irimia, Pablo Iglesias, Fernando Guerrero-Peral, Ángel Luis Belvís, Robert Pozo-Rosich, Patricia Pascual, Julio Santos-Lasaosa, Sonia Universidad de Zaragoza (orcid)0000-0001-5139-6031 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 15 (2024), [7 pp.] Front. neurol. Frontiers in Neurology 1664-2295 295426 http://zaguan.unizar.es/record/136197/files/texto_completo.pdf Versión publicada 2385934 http://zaguan.unizar.es/record/136197/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:136197 articulos driver 2026-02-17-20:37:51 ARTICLE